REGN vs RPRX
Regeneron Pharmaceuticals and Royalty Pharma plc, both Healthcare
Regeneron Pharmaceuticals is the larger company at $64B against $31B. On trailing earnings REGN is the cheaper of the two at a P/E of 18.4 against 30.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year RPRX returned +59% against +25% for REGN. The RyuScore puts REGN ahead, 70 against 52 out of 100.
| Figure | REGN | RPRX |
|---|---|---|
| Last close | $746 | $56.90 |
| Market cap | $64B | $31B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.4 | 30.3 |
| 1-year return | +25% | +59% |
| 5-year return | +18% | +61% |
| RyuScoresector-relative, 1–10 | 70/100 | 52/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Regeneron Pharmaceuticals
Revenue of $4.3B in Q2 2026, net income $1.3B. Its largest reported line is Share Of Profit Losses, 50% of the disclosed total.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.